Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

Gene Signature-Based Drug Repositioning

Drugsig: A Resource For Computational Drug Repositioning Utilizing Gene Expression Signatures

A Review of Drug Repositioning Based Chemical-induced Cell Line Expression Data

Integrating population-level and cell-based signatures for drug repositioning

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension

A Pathway Profile-Based Method for Drug Repositioning

Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine

In silico drug repositioning based on drug-miRNA associations

PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool

Turning genome-wide association study findings into opportunities for drug repositioning

Unlocking the potential of signature-based drug repurposing for anticancer drug discovery

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

System biology approaches for drug repurposing

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

A drug repurposing method based on inhibition effect on gene regulatory network

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds

A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm

High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming